MALATTIE EPATICHE ASSOCIATE AD ALCOL: UN RUOLO PER GLI AGONISTI DEI RECETTORI GLP-1 ! DA” THE LANCET gastroenterology & hepatology””

DISPEPSIA, EPATOLOGIA, EPATOLOGIA ONCOLOGICA, GASTROENTEROLOGIA, MEDICI DI FAMIGLIA, MEDICINA INTERNA, NEWSLETTER, Senza categoria

GLP-1 receptor agonists in alcohol use disorder and alcohol-associated liver disease Ashwani K Singal, Lorenzo Leggio GLP-1 is a hormone produced by intestinal L-type enteroendocrine cells, endocrine pancreas, and nucleus tractus solitarius neurons in the brain. GLP-1 acts via the GLP-1 receptor and provides beneficial effects on food intake, energy homoeostasis, glucose metabolism, hepatic function,…

COLANGITE BILIARE PRIMITIVA (CBP). E’ TEMPO DI RIPENSARE AL RUOLO DEL BEZAFIBRATO! UN’OTTIMO EDITORIALE DA “Nat Rev Gastroenterol Hepatol” purtroppo non-free

EPATOLOGIA, EPATOLOGIA ONCOLOGICA, GASTROENTEROLOGIA, NEWSLETTER

Bezafibrate for primary biliary cholangitis: time to act on the evidence Christophe Corpechot et al. After the regulatory rejection of obeticholic acid, peroxisome proliferator-activated receptor (PPAR) agonists have emerged as the leading second-line candidates for primary biliary cholangitis, pending defnitive approval. Of these, only bezafbrate — a low-cost, widely available generic — has demonstrated long-term…

INTELLIGENZA ARTIFICIALE E COLONSCOPIA: L’USO DELLA IA PUO’ PROVOCARE UN CALO DELLA CAPACITA’ DI IDENTIFICARE ADENOMI IN CORSO DI COLONSCOPIA SENZA IA (DESKILLING)! DA”LANCET GASTRO&HEP”

AI, INTELLIGENZA ARTIFICIALE, ENDOSCOPIA, GASTROENTEROLOGIA, NEWSLETTER, ONCOLOGIA

Endoscopist deskilling risk after exposure to artificial intelligence in colonoscopy: a multicentre, observational study Krzysztof Budzyń, et al. Summary Background It is not known if continuous exposure to artificial intelligence (AI) changes endoscopists’ behaviour when conducting colonoscopy. We assessed how endoscopists who regularly used AI performed colonoscopy when AI was not in use. Methods We…

INTELLIGENZA ARTIFICIALE E MEDICINA PERSONALIZZATA PER LE IBD: OCCHIO AL FUTURO CHE E’ GIA QUI ! DA” GASTROENTEROLOGY” (FREE)

AI, INTELLIGENZA ARTIFICIALE, GASTROENTEROLOGIA, IBD, NEWSLETTER

Artificial Intelligence–Driven Personalized Medicine: Transforming Clinical Practice in Inflammatory Bowel Disease Marietta Iacucci et al. Abstract Inflammatory bowel disease is marked by significant clinical heterogeneity, posing challenges for accurate diagnosis and personalized treatment strategies. Conventional approaches, such as endoscopy and histology, often fail to adequately and accurately predict medium- and long-term outcomes, leading to suboptimal…

INTELLIGENZA ARTIFICIALE ED EPATOPATIE CRONICHE (INCLUSA MASLD): ATTENZIONE IL NUOVO E’ IN ARRIVO! TOCCA LAVORARCI. DA “GASTROENTEROLOGY” (FREE)

AI, INTELLIGENZA ARTIFICIALE, CHIRURGIA, EPATOLOGIA, EPATOLOGIA ONCOLOGICA, NEWSLETTER

The Role of Artificial Intelligence in Chronic Liver Diseases and Liver Transplantation Ashley Spann et al. Abstract Background & Aims In hepatology, pattern recognition in laboratory data and clinical characteristics is the hallmark of clinical care. Artificial intelligence (AI) tools, like machine or deep learning and large language models, provide interesting mechanisms for facilitating care advancement.…

DIARREA DA CHEMIOTERAPIA O DA CHEMIORADIOTERAPIA: PENSATE ALLA GLUTAMINA! UNA META-ANALISI. DA”BMC Gastroenterology” (FREE)

GASTROENTEROLOGIA, IBS, MEDICI DI FAMIGLIA, NEWSLETTER, Senza categoria

Glutamine prevents diarrhea in colorectal cancer patients undergoing chemotherapy or chemoradiotherapy: a meta-analysis Lijuan Chen et al. Abstract Objective To assess the efficacy of glutamine in preventing diarrhea associated with chemotherapy or chemoradiotherapy in colorectal cancer. Methods Randomized controlled trials of glutamine in the prevention of chemotherapy-associated diarrhea of colorectal cancer were retrieved from the…